Contact
searchSearch
HMP Global
Login

Head and Neck Cancer

Featured

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022
Yvette C. Terrie, BS Pharm, RPh
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022
Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022
Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022
Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
03/24/2021
Janelle Bradley
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021
Janelle Bradley
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Cetuximab vs Cisplatin for Locoregional Control of HNSCC
02/01/2021
02/01/2021
Journal of Clinical Pathways

Newsfeed

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022
Yvette C. Terrie, BS Pharm, RPh
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022
Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022
Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022
Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
News
Deep Learning Models for Image-Guided RT in Head and Neck and Prostate Cancers
12/10/2020
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve...
12/10/2020
Journal of Clinical Pathways
News
Financial Navigation Not Associated With Reduced Financial Hardship
08/03/2026
Rebecca Amrick
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association...
08/03/2026
Journal of Clinical Pathways
News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways
News
Medicare’s Oncology Care Model Demonstrated Modest Payment Reductions for Patients Receiving Chemotherapy
07/24/2026
Rebecca Amrick
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s...
07/24/2026
Journal of Clinical Pathways
News
Selinexor Plus Ruxolitinib Demonstrates Improved Efficacy in Patients With Myelofibrosis
07/22/2026
Rebecca Amrick
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib...
07/22/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
News
APP-Led Benign Hematology Consults Improve Access in Community Oncology, Study Finds
07/16/2026
Grace Taylor, MS, MA
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The...
07/16/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Distress Thermometer Scores Highlight Association Between Psychosocial Distress and Survival Outcomes for Cancer Patients
07/13/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses...
07/13/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use